ID   HAK-1B
AC   CVCL_7958
DR   cancercelllines; CVCL_7958
DR   Wikidata; Q54872379
RX   PubMed=7537711;
RX   PubMed=8393423;
RX   PubMed=9023415;
RX   PubMed=9178645;
RX   PubMed=10347112;
RX   PubMed=27329724;
CC   Population: Japanese.
CC   Doubling time: 11 hours (Note=At 19th passage) (PubMed=8393423).
CC   HLA typing: A*02:01,33:02; B*44:03:01,54:01; C*01:02,14:03; DQA1*01:01,01:02; DQB1*06:02,06:04; DRB1*13:02,15:01 (PubMed=9178645).
CC   Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Cys242Tyr (c.725G>A); ClinVar=VCV000012354; Zygosity=Unspecified (PubMed=8393423).
CC   Derived from site: In situ; Liver; UBERON=UBERON_0002107.
DI   NCIt; C3098; Hepatitis C infection
DI   NCIt; C7956; Adult hepatocellular carcinoma
DI   ORDO; Orphanet_210159; Adult hepatocellular carcinoma
OX   NCBI_TaxID=9606; ! Homo sapiens (Human)
OI   CVCL_7957 ! HAK-1A
SX   Male
AG   55Y
CA   Cancer cell line
DT   Created: 04-04-12; Last updated: 05-10-23; Version: 18
//
RX   PubMed=7537711; DOI=10.1002/hep.1840210510;
RA   Haramaki M., Yano H., Fukuda K., Momosaki S., Ogasawara S., Kojiro M.;
RT   "Expression of CD44 in human hepatocellular carcinoma cell lines.";
RL   Hepatology 21:1276-1284(1995).
//
RX   PubMed=8393423; DOI=10.1002/hep.1840180216;
RA   Yano H., Iemura A., Fukuda K., Mizoguchi A., Haramaki M., Kojiro M.;
RT   "Establishment of two distinct human hepatocellular carcinoma cell
RT   lines from a single nodule showing clonal dedifferentiation of cancer
RT   cells.";
RL   Hepatology 18:320-327(1993).
//
RX   PubMed=9023415; DOI=10.1006/cimm.1996.1062;
RA   Seki N., Hoshino T., Kikuchi M., Hayashi A., Itoh K.;
RT   "HLA-A locus-restricted and tumor-specific CTLs in tumor-infiltrating
RT   lymphocytes of patients with non-small cell lung cancer.";
RL   Cell. Immunol. 175:101-110(1997).
//
RX   PubMed=9178645; DOI=10.1006/cimm.1997.1108;
RA   Nakao M., Sata M., Saitsu H., Yutani S., Kawamoto M., Kojiro M.,
RA   Itoh K.;
RT   "CD4+ hepatic cancer-specific cytotoxic T lymphocytes in patients with
RT   hepatocellular carcinoma.";
RL   Cell. Immunol. 177:176-181(1997).
//
RX   PubMed=10347112; DOI=10.1002/hep.510290624;
RA   Yano H., Iemura A., Haramaki M., Ogasawara S., Takayama A., Akiba J.,
RA   Kojiro M.;
RT   "Interferon alfa receptor expression and growth inhibition by
RT   interferon alfa in human liver cancer cell lines.";
RL   Hepatology 29:1708-1717(1999).
//
RX   PubMed=27329724; DOI=10.18632/oncotarget.10161;
RA   Watari K., Nishitani A., Shibata T., Noda M., Kawahara A., Akiba J.,
RA   Murakami Y., Yano H., Kuwano M., Ono M.;
RT   "Phosphorylation of mTOR Ser2481 is a key target limiting the efficacy
RT   of rapalogs for treating hepatocellular carcinoma.";
RL   Oncotarget 7:47403-47417(2016).
//